Does fisetin from strawberries really work as a zombie-cell cleaner?

Fisetin is a natural compound found in strawberries, but also in apples, onions and other plants. In laboratory research it was tested alongside nine other flavonoids, and it proved to be the most potent so-called 'senolytic': a substance that selectively clears out aged, no-longer-functioning cells (also known as zombie cells or senescent cells). In cell cultures from both mice and humans, fisetin measurably reduced the presence of senescence markers, and zombie cells were also reduced in human adipose tissue¹. That is a concrete positive result, but it comes from laboratory and tissue research, not from a clinical study.

In mouse studies the findings are strikingly consistent. Old mice that received fisetin late in life lived longer on average and also reached a higher maximum lifespan. Their tissue health improved and age-related abnormalities decreased¹. Another mouse study showed that an intermittent schedule (one week of fisetin, two weeks off, one week of fisetin) reduced arterial stiffness and improved vascular function, through greater production of nitric oxide and less oxidative damage². Age-related changes in blood proteins also reversed following acute fisetin treatment in mice³. These mouse results are biologically coherent and have been replicated across multiple studies, but they do not automatically translate to humans.

In humans, research is still at a very early stage. Phase I/II clinical trials are underway, but definitive conclusions about safety, effective dosing and efficacy in humans are not yet available⁴. Early pilot studies with senolytics in general, including fisetin, show positive signals: fewer zombie cells, lower inflammatory markers and fewer complaints of frailty in older people⁵. However, the researchers conducting these trials state explicitly that use outside controlled clinical studies is premature for the time being.

There are also safety questions that need to be taken seriously. Senolytics as a class are associated with thrombocytopenia, a shortage of platelets, and the dosing schedule (continuous versus intermittent) affects both efficacy and side effects⁶. Side effects of fisetin specifically in humans have not yet been studied sufficiently. The optimal dose is unknown. Anyone taking fisetin as a supplement is therefore doing so outside the scope of available clinical knowledge.

Mouse studies have also examined fisetin in the context of serious infections: senolytics reduced COVID-related mortality in old mice⁷. This is an early animal study finding without human clinical evidence, and it is too soon to draw any practical conclusions from it. In summary: the rationale behind fisetin as a zombie-cell cleaner is biologically supported and the mouse data are promising, but for humans the efficacy has not yet been proven and the safety profile has not yet been adequately mapped.